1,722,686 research outputs found
Software modernization powered by Dynamic Language Product Lines
<p>Reproducibility package for the paper </p>
<p> "Software modernization powered by Context-Aware Language Product Lines"<br> Walter Cazzola and Luca Favalli</p>
<p>currently submitted to Journal of Systems and Software.</p>
Dr. Favalli, et al. reply
We thank Dr. So, et al1 for the interest in our letter2 and for sharing the results about the coronavirus disease 2019 (COVID-19) in patients with systemic lupus erythematosus (SLE) in Hong Kong1 We agree that the quantification of the risk of infection with severe acute respiratory coronaviruses-2 (SARS-CoV-2) in patients with SLE is a major concern
capitoli: La contrattazione di solidarietà (p. 872 – 903); Le misure di sostegno al reddito contro la disoccupazione involontaria (p. 904 – 931); L’outplacement individuale (p. 932 – 943); (con G. Favalli) I diritti sindacali (p. 36 – 95); (con G. Favalli) La libertà sindacale(p. 96 – 109); (con G. Favalli) Cessione del contratto di lavoro (p. 726 – 733); (con G. Favalli) Collegamento societario (p. 828 – 837); (con G. Favalli) Il collocamento dei lavoratori stranieri in Italia (p. 1304 – 1319)
Il diritto al gratuito patrocinio nella riforma del Sistema europeo comune di asilo (SECA): un passo avanti e due indietro?
This article purports to analyse the right to legal aid for applicants of
international protection in the prospective reform of the Common European asylum
system (CEAS). The overall aim is to point out that, despite several shortcomings, the
CEAS reform also provides some promising innovations, which are further developing
within the institutional debate. Among others, it emerges the implementation of the
right to access to justice and to legal aid of the applicants for international protection in
the context of the asylum procedure
Understanding the Role of Interleukin-6 (IL-6) in the Joint and Beyond: A Comprehensive Review of IL-6 Inhibition for the Management of Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a chronic, debilitating autoimmune disorder involving inflammation and progressive destruction of the joints, affecting up to 1% of the population. The majority of patients with RA have one or more comorbid conditions, the most common being cardiovascular disease, osteoporosis, and depression, the presence of which are associated with poorer clinical outcomes and lower health-related quality of life. RA pathogenesis is driven by a complex network of proinflammatory cells and cytokines, and of these, interleukin-6 (IL-6) plays a key role in the chronic inflammation associated with RA. Through cell signaling that can be initiated by both membrane-bound and soluble forms of its receptor, IL-6 acts both locally to promote joint inflammation and destruction, and in the circulation to mediate extra-articular manifestations of RA, including pain, fatigue, morning stiffness, anemia, and weight loss. This narrative review describes the role of IL-6 in the pathogenesis of RA, its comorbidities, and extra-articular systemic manifestations, and examines the effects of the IL-6 receptor inhibitors sarilumab and tocilizumab on clinical endpoints of RA, patient-reported outcomes, and common comorbidities and extra-articular manifestations
Il ruolo della convenzione delle Nazioni Unite sui diritti delle persone con disabilità ed il modello dei diritti umani
Comunicazione orientativa della commissione europea sulla direttiva 2005/29/CE relativa alle pratiche commerciali sleali delle imprese nei confronti dei consumatori,
- …
